Tobira Therapeutics, Inc. Common Stock
TBRA
TBRA was delisted on the 31st of October, 2016.
45 hedge funds and large institutions have $147M invested in Tobira Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 11 closing their positions.
60% more capital invested
Capital invested by funds: $91.7M → $147M (+$54.9M)
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
2% less funds holding
Funds holding: 46 → 45 (-1)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$4.36M |
| 2 |
Axa
Paris,
France
|
+$2.57M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.53M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.52M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.37M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.82M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$1.44M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.25M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$818K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| – | -$25K | -3,025 | Closed |
|
52
Citigroup
New York
| – | -$15K | -1,838 | Closed |
|
|
BJ
53
BlackRock Japan
Tokyo,
Japan
| – | -$14K | -1,731 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$8K | -1,019 | Closed |
|
55
Wells Fargo
San Francisco,
California
| – | -$2K | -270 | Closed |
|
|
CSS
56
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$2K | -216 | Closed |
|
TBRA Hedge Fund Activity: Q2 2016 in Review
45 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q2 2016, worth a combined $147M — up 60% from $91.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TBRA and 10 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 17 added.
The largest buyer was BB Biotech, opening a new position worth an estimated $4.36M. The largest seller was Novo Holdings A/S, cutting an estimated $2.37M.
- 45 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q2 2016, down from 46 in Q1 2016.
- Funds reported $147M of Tobira Therapeutics, Inc. Common Stock stock for Q2 2016, up 60% quarter-over-quarter.
- 10 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q2 2016 and 11 closed out, a net change of -1 holder.
- The largest Tobira Therapeutics, Inc. Common Stock buyer in Q2 2016 was BB Biotech, an estimated $4.36M added.
- The largest Tobira Therapeutics, Inc. Common Stock seller in Q2 2016 was Novo Holdings A/S, an estimated $2.37M sold.
Based on aggregated 13F filings for Q2 2016.